Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants

NCT05550129 | Completed Phase 1 FDA Drug

• 1 other identifier: 20190317
• Study Type: interventional
• Target: 13
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objectives of this study are to evaluate the effect of AMG 510 on the pharmacokinetics (PK) of metformin in healthy participants and to evaluate the effect of metformin on the PK of AMG 510 in healthy participants.

Conditions

Healthy Volunteers

Keywords

Healthy volunteers; AMG 510; Metformin

Outcome Measures

Primary Outcomes (6)

• Maximum Plasma Concentration (Cmax) of Metformin

  Day 1 and Day 8

• Area Under the Plasma Concentration Time Curve (AUC) from Time Zero to the Last Quantifiable Concentration (AUClast) of Metformin

  Day 1 and Day 8

• AUC from Time Zero to Infinity (AUCinf) of Metformin

  Day 1 and Day 8

• Cmax of AMG 510

  Day 4 and Day 8

• AUClast of AMG 510

  Day 4 and Day 8

• AUCinf of AMG 510

  Day 4 and Day 8

Secondary Outcomes (8)

• Number of Participants with an Adverse Event (AE)

  Day 1 to Day 10

• Plasma Concentration of AMG 510 Metabolite M24

  Day 4 and Day 8

• Urine Concentration of Metformin

  Day 1 and Day 8

• Cmax of Metformin

  Day 4 and Day 8

• AUClast of Metformin

  Day 4 and Day 8

Study Arms (1)

AMG 510 + Metformin

EXPERIMENTAL

Drug: AMG 510; Drug: Metformin

Interventions

AMG 510 DRUG

Oral tablet

AMG 510 + Metformin

Metformin DRUG

Oral tablet

AMG 510 + Metformin

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male participants or female participants, between 18 and 60 years of age (inclusive), at the time of Screening.
• Body mass index, between 18 and 30 kg/m\^2 (inclusive), at the time of Screening.
• Females of nonchildbearing potential.

You may not qualify if:

• Inability to swallow oral medication or history of malabsorption syndrome.
• History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.
• Poor peripheral venous access.
• History or evidence, at Screening or Check in, of clinically significant disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.

Sponsors & Collaborators

• Amgen: lead

Study Sites (1)

Covance Clinical Research Unit

Madison, Wisconsin, 53704, United States

Location

Related Links

• AmgenTrials clinical trials website

MeSH Terms

Interventions

sotorasib; Metformin

Intervention Hierarchy (Ancestors)

Biguanides; Guanidines; Amidines; Organic Chemicals

Study Officials

• MD

  Amgen

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 19, 2022
• First Posted: September 22, 2022
• Study Start: November 13, 2019
• Primary Completion: November 25, 2019
• Study Completion: November 25, 2019
• Last Updated: March 5, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
• Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Locations

US (1)